How much has Schrödinger raised?
Schrödinger is a public company (Nasdaq: SDGR), so the most useful current funding read is its filings, revenue scale, cash flow, guidance, and acquisition capacity rather than private round totals.
- Total raised
- Public company; private total not the current constraint
- Disclosed rounds
- Pre-IPO/private history plus public filings
- Latest round
- Public-market financing and operating cash flow
- Latest valuation
- Nasdaq: SDGR
- First raised
- 1990
- Notable backer
- Public shareholders
Schrödinger's funding rounds
Schrödinger's capital path moved from founding and growth capital into public-company financing.
- 1990FoundedSchrödinger begins commercializing computational chemistry software.
- 2018Strategic collaborationsPharma collaborations support platform validation and economics.
- 2020IPOSchrödinger lists on Nasdaq under SDGR.
- 2025Full-year resultsSchrödinger reports $256M total revenue and $200M software revenue.
- 2026Hosted transitionThe company continues moving customers toward ratable hosted software licensing.
Sources:Schrödinger FY 2025 resultsSchrödinger investor relations
How much has Schrödinger raised in total?
Schrödinger is best analyzed as a public company as of June 2026. Any pre-IPO venture or private-equity history is less useful for current selling than the company's listed status, revenue base, cash generation, debt capacity, and investor commitments.
The current scale marker is $256M 2025 total revenue; $200M 2025 software revenue. That tells sellers the company can fund enterprise purchases, but those purchases must survive budget ownership, procurement, security, compliance, and ROI review.
Who are Schrödinger's investors?
The relevant investor base is the public shareholder base behind Nasdaq: SDGR. Management teams at this stage are accountable to public-market expectations for growth, margin, cash flow, guidance, and risk control.
That accountability affects buying behavior: projects tied to reported metrics, margin expansion, regulatory readiness, or customer growth are easier to justify than speculative tooling.
Why did valuation or capital priorities move?
Valuation for a public healthcare company moves with growth, margins, reimbursement, utilization, clinical evidence, customer retention, regulatory risk, and capital-market sentiment. Schrödinger's latest public materials emphasize $256M 2025 total revenue; $200M 2025 software revenue, which is the clearest factual anchor for current account planning.
For seller strategy, avoid treating valuation as the budget. Translate the company's stated operating priorities into a business case owned by a specific executive function.
Is Schrödinger profitable, and will it need more capital?
Profitability and capital needs should be read from the latest annual report, quarterly results, cash-flow statement, and guidance. Public healthcare and life-science companies can have revenue scale while still prioritizing profitability, cash preservation, restructuring, R&D, or commercial expansion.
The safe sales assumption is mature budget governance: finance will ask why the project matters now, what metric it moves, and how implementation risk is controlled.
What does Schrödinger's funding mean if you sell into them?
The seller signal is buying capacity with a high proof bar. Schrödinger can fund software, data, services, infrastructure, compliance, clinical, and go-to-market projects when they match a board-visible or executive-visible priority.
Procurement is likely to favor vendors with healthcare references, security documentation, integration readiness, implementation support, and clear commercial terms.
As of June 2026.Sources:Schrödinger FY 2025 resultsSchrödinger investor relations
Schrödinger — frequently asked questions
